According to a newly published market research report by 24LifeSciences, global glycated hemoglobin testing market was valued at USD 322 million in 2024 and is projected to reach USD 530 million by 2031, growing at a compound annual growth rate (CAGR) of 7.6% during the forecast period 2025-2031.

Glycated hemoglobin (HbA1c) testing serves as the gold standard for diabetes management worldwide, measuring average blood glucose levels over a 3-month period. This biochemical test analyzes hemoglobin molecules that have glucose permanently attached (glycated), providing clinicians with a more reliable indicator than single-point glucose measurements. With diabetes prevalence exceeding 537 million cases globally as of 2023, HbA1c testing has become fundamental for both diagnosis and treatment monitoring in diabetes care protocols.

Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/15484/glycated-hemoglobin-testing-market

Global Diabetes Epidemic Drives Market Expansion

The diabetes pandemic remains the primary growth engine for the HbA1c testing market, with the International Diabetes Federation projecting cases to reach 643 million by 2030. This exponential growth correlates directly with increasing testing volumes, as clinical guidelines now recommend quarterly HbA1c monitoring for all diabetics. The test's unique ability to reflect long-term glycemic control makes it indispensable for treatment adjustment and complication prevention.

Healthcare policy changes have further accelerated adoption, with most developed countries incorporating HbA1c testing into national diabetes screening programs. The American Diabetes Association's recommendation to use HbA1c for diabetes diagnosis (6.5%) has significantly expanded testing beyond monitoring applications.

Technological Advancements Transform Testing Capabilities

Recent innovations have revolutionized HbA1c testing, particularly in point-of-care devices that deliver lab-comparable results in under 6 minutes. Modern analyzers now achieve <3% coefficient of variation, meeting stringent National Glycohemoglobin Standardization Program (NGSP) requirements. These devices utilize advanced methodologies ranging from immunoassays to capillary electrophoresis, each offering distinct advantages in accuracy and throughput.

The industry has seen notable progress in automated high-throughput systems that process hundreds of samples hourly, coupled with middleware solutions for seamless laboratory information system integration. Simultaneously, compact analyzers designed for physician offices and pharmacies are expanding testing accessibility while maintaining diagnostic-grade precision.

Market Challenges: Regulatory Hurdles and Accuracy Concerns

Despite robust growth, several factors constrain market potential:

  • Regulatory complexities for device approvals (FDA CLIA moderate/high complexity classifications)

  • Hemoglobin variants interference affecting certain testing methodologies

  • Reimbursement limitations in developing healthcare systems

  • High capital costs for laboratory-grade analyzers ($15,000-$75,000)

The market also faces intensifying competition from continuous glucose monitoring systems, although HbA1c testing maintains its position as the definitive endpoint for glycemic control assessment.

Get the Complete Report & Table of Contents: https://www.24lifesciences.com/glycated-hemoglobin-testing-market-15484

North America Dominates; Asia-Pacific Shows Highest Growth Potential

North America currently commands approximately 42% of global market share, supported by advanced healthcare infrastructure, comprehensive insurance coverage, and high diabetes awareness. The U.S. represents the largest national market, with an estimated 38 million diabetics requiring regular monitoring.

The Asia-Pacific region demonstrates the most dynamic growth, forecast at 9.2% CAGR, driven by:

  • Rapidly increasing diabetes prevalence in India and China

  • Expanding middle-class access to diagnostic services

  • Government initiatives for diabetes screening and management

  • Growing hospital and private laboratory networks

Europe maintains steady growth through universal healthcare systems ensuring broad testing accessibility, while Latin America and Middle East markets show gradual expansion alongside healthcare infrastructure development.

Laboratory Testing Holds Majority Share

By testing setting, central laboratories continue processing the majority of HbA1c tests (68% share), preferred for their high-volume efficiency and ability to handle complex cases requiring specialized methodologies. However, point-of-care testing has emerged as the fastest-growing segment (8.3% CAGR), particularly valuable for immediate clinical decision-making in diabetes clinics and emergency settings.

Hospitals account for the dominant application segment (45% share), followed by independent diagnostic centers and physician offices. The treatment monitoring indication represents the primary use case (62% of tests), while diagnostic applications continue gaining ground following ADA guideline adoption.

Competitive Landscape: Consolidation Among Diagnostics Leaders

The global HbA1c testing market features a semi-consolidated structure, with the top five manufacturers controlling approximately 60% of total revenue. Competition centers on methodology accuracy, automation levels, regulatory approvals, and test menu breadth.

Leading companies profiled in the report include:

  • Abbott Laboratories

  • F. Hoffmann-La Roche

  • Bio-Rad Laboratories

  • Danaher Corporation (Beckman Coulter)

  • Siemens Healthineers

  • EKF Diagnostics

  • Tosoh Bioscience

  • Arkray

  • Other prominent players

Recent industry trends include portfolio diversification (integrating HbA1c with lipid/renal panels), strategic acquisitions to expand geographic presence, and digital health integration enabling remote test result access.

Emerging Opportunities in Preventive Care and Risk Stratification

Beyond diabetes management, HbA1c testing is gaining recognition for cardiovascular risk assessment, with studies establishing clear correlations between elevated levels and adverse cardiac outcomes. This dual diagnostic application creates new growth avenues in:

  • Corporate wellness programs incorporating metabolic health screening

  • Integrated care models for chronic disease prevention

  • Retail health clinics offering comprehensive check-ups

The development of disposable cartridge-based systems and CLIA-waived devices is poised to further decentralize testing, potentially expanding the market to non-traditional settings like pharmacies and workplaces.

Access the Full Market Intelligence Report

Download a Free Sample Report (PDF):
https://www.24lifesciences.com/download-sample/15484/glycated-hemoglobin-testing-market

Get the Complete Report & Table of Contents:
https://www.24lifesciences.com/glycated-hemoglobin-testing-market-15484

About 24LifeSciences

24LifeSciencesis a leading provider of market intelligence and strategic research reports across pharmaceuticals, biotechnology, medical devices, and healthcare technologies. Our reports are designed to support data-driven decision-making for manufacturers, healthcare providers, investors, consultants, and policy makers worldwide.

Follow us on LinkedIn:
https://www.linkedin.com/company/lifesciences24/